Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients - PubMed (original) (raw)
Clinical Trial
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients
M Hassan Alin et al. Trans R Soc Trop Med Hyg. 1996 Jan-Feb.
Abstract
The study compared the clinical efficacy and safety of oral artemisinin and oral artesunate as well as artemisinin pharmacokinetics during and after resolution of falciparum malaria. Forty adults with symptomatic falciparum malaria were allocated at random to treatment with either oral artemisinin (500 mg single dose on day 1 followed by 250 mg twice daily for 4 d and then another 500 mg single dose on day 6) or with oral artesunate (100 mg single dose on day 1 followed by 50 mg twice daily for 5 d). Patients were admitted to hospital at the Kibaha Designated District Hospital, Kibaha, Tanzania for the duration of treatment. The patients were seen once weekly for 3 more weeks. The time to parasite clearance (PCT) after oral artesunate (26.4 +/- 3.6 h) was shorter (P = 0.002) than after artemisinin (31 +/- 3.6 h). The fever subsidence time (FST) after oral artesunate (18.9 +/- 4.0 h) was also shorter (P = 0.04) than after artemisinin (21.8 +/- 4.6 h). Parasites were detected in 4 (20%) and 7 (35%) patients after completing treatment with artesunate and artemisinin respectively. In these patients the parasitaemia reappeared at the 3rd or 4th week of follow-up. Standard haematology, blood biochemistry and urinalysis, performed before drug intake and again on days 6 and 14, were normal. No clinical abnormality was observed during the study period. Artemisinin plasma concentrations, determined by high performance liquid chromatography with post-column derivatization and detection by ultraviolet light, were followed up to 8 h after drug administration on days 1 and 6. Artemisinin absorption was rapid, the maximum plasma concentrations (Cmax) being attained at about 3 h. Artemisinin areas under the plasma concentration-time curve (AUC) and the Cmax values were about 6 times higher after the first dose on day 1 than on day 6. This decrease in artemisinin plasma concentration is suggestive of an increase in metabolic capacity due to pronounced autoinduction.
Similar articles
- Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria.
Alin MH, Ashton M, Kihamia CM, Mtey GJ, Björkman A. Alin MH, et al. Br J Clin Pharmacol. 1996 Jun;41(6):587-92. doi: 10.1046/j.1365-2125.1996.35116.x. Br J Clin Pharmacol. 1996. PMID: 8799526 Free PMC article. Clinical Trial. - Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine.
Alin MH, Kihamia CM, Bjorkman A, Bwijo BA, Premji Z, Mtey GJ, Ashton M. Alin MH, et al. Am J Trop Med Hyg. 1995 Dec;53(6):639-45. doi: 10.4269/ajtmh.1995.53.639. Am J Trop Med Hyg. 1995. PMID: 8561267 Clinical Trial. - Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria.
Karbwang J, Na-Bangchang K, Thanavibul A, Bunnag D, Chongsuphajaisiddhi T, Harinasuta T. Karbwang J, et al. Bull World Health Organ. 1994;72(2):233-8. Bull World Health Organ. 1994. PMID: 8205643 Free PMC article. Clinical Trial. - Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.
Bustos MD, Wongsrichanalai C, Delacollette C, Burkholder B. Bustos MD, et al. Southeast Asian J Trop Med Public Health. 2013;44 Suppl 1:201-30; discussion 306-7. Southeast Asian J Trop Med Public Health. 2013. PMID: 24159833 Review. - Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria.
de Vries PJ, Dien TK. de Vries PJ, et al. Drugs. 1996 Dec;52(6):818-36. doi: 10.2165/00003495-199652060-00004. Drugs. 1996. PMID: 8957153 Review.
Cited by
- Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure.
Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. Teuscher F, et al. J Infect Dis. 2010 Nov 1;202(9):1362-8. doi: 10.1086/656476. J Infect Dis. 2010. PMID: 20863228 Free PMC article. - Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon.
Borrmann S, Adegnika AA, Missinou MA, Binder RK, Issifou S, Schindler A, Matsiegui PB, Kun JF, Krishna S, Lell B, Kremsner PG. Borrmann S, et al. Antimicrob Agents Chemother. 2003 Mar;47(3):901-4. doi: 10.1128/AAC.47.3.901-904.2003. Antimicrob Agents Chemother. 2003. PMID: 12604519 Free PMC article. - Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.
Ericsson T, Blank A, von Hagens C, Ashton M, Äbelö A. Ericsson T, et al. Eur J Clin Pharmacol. 2014 Dec;70(12):1453-63. doi: 10.1007/s00228-014-1754-2. Epub 2014 Sep 25. Eur J Clin Pharmacol. 2014. PMID: 25248945 Clinical Trial. - Pregnane X receptor and natural products: beyond drug-drug interactions.
Staudinger JL, Ding X, Lichti K. Staudinger JL, et al. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):847-57. doi: 10.1517/17425255.2.6.847. Expert Opin Drug Metab Toxicol. 2006. PMID: 17125405 Free PMC article. Review. - Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics.
de Vries PJ, Bich NN, Van Thien H, Hung LN, Anh TK, Kager PA, Heisterkamp SH. de Vries PJ, et al. Antimicrob Agents Chemother. 2000 May;44(5):1302-8. doi: 10.1128/AAC.44.5.1302-1308.2000. Antimicrob Agents Chemother. 2000. PMID: 10770766 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous